References
- ObergKNeuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approachesCurr Opin Oncol201224443344022510940
- BosmanFTCarneiroFHrubanRHTheiseNDWHO classification of tumours of the digestive systemCAB Direct2010417
- BernickPEKlimstraDSShiaJNeuroendocrine carcinomas of the colon and rectumDis Colon Rectum200447216316915043285
- BrennerBShahMAGonenMKlimstraDSShiaJKelsenDPSmall-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 casesBr J Cancer20049091720172615150595
- BurkeABShekitkaKMSobinLHSobin Small cell carcinomas of the large intestineAm J Clin Pathol19919533153211847579
- AhlmanHNilssonOMcNicolAMPoorly-differentiated endocrine carcinomas of midgut and hindgut originNeuroendocrinology2008871404617940332
- MitryERougierPThe treatment of undifferentiated neuroendocrine tumorsCrit Rev Oncol Hematol2001371475111164718
- MavroudisDPapadakisEVeslemesMA multicenter randomized clinical trial comparing paclitaxel–cisplatin etoposide versus cisplatin–etoposide as first-line treatment in patients with small-cell lung cancerAnn Oncol200112446347011398877
- MoertelCGKvolsLKO’ConnellMJRubinJTreatment of neuroen-docrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasmsCancer19916822272321712661
- MitryEBaudinEDucreuxMTreatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatinBr J Cancer19998181351135510604732
- FjällskogMLGranbergDPWelinSLTreatment with cisplatin and etoposide in patients with neuroendocrine tumorsCancer20019251101110711571721
- IwasaSMorizaneCOkusakaTCisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreasJpn J Clin Oncol201040431331820047862
- TherassePArbuckSGEisenhauerEANewguidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
- NilssonOVan CutsemEDelle FaveGPoorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic)Neuroendocrinology200684321221517312381
- PizziSAzzoniCBassiDBottarelliLMilioneMBordiCGenetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tractCancer20039861273128212973852
- LuZHLiJLuMFeasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomasMed Oncol201330366423864251
- SorbyeHStrosbergJBaudinEKlimstraDSYaoJCGastroenteropan-creatic high-grade neuroendocrine carcinomaCancer2014120182814282324771552
- BahriHLaurenceLEdelineJHigh prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluationJ Nucl Med201455111786179025286923
- InomataMHayashiRTokuiKOutcome and prognostic factors in patients with small cell lung cancer who receive third-linechemo-therapyTumori2014100550751125343544
- CihanYBRelationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapyAsian Pac J Cancer Prev201415104233423824935376
- BougnouxPGermainEChajèsVCytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinomaBr J Cancer19997911–121765176910206290
- VolkovaERobinsonBAWillisJCurrieMJDachsGUMarginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cellsOncol Lett20147231132024396438